- Home
- HOND vs TSHA Comparison
HOND vs TSHA Comparison
Compare HOND & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOND
- TSHA
- Stock Information
- Founded
- HOND 2024
- TSHA 2019
- Country
- HOND United States
- TSHA United States
- Employees
- HOND N/A
- TSHA N/A
- Industry
- HOND
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- HOND
- TSHA Health Care
- Exchange
- HOND NYSE
- TSHA Nasdaq
- Market Cap
- HOND 290.9M
- TSHA 334.1M
- IPO Year
- HOND 2024
- TSHA 2020
- Fundamental
- Price
- HOND $10.11
- TSHA $1.61
- Analyst Decision
- HOND
- TSHA Strong Buy
- Analyst Count
- HOND 0
- TSHA 8
- Target Price
- HOND N/A
- TSHA $6.63
- AVG Volume (30 Days)
- HOND 1.5K
- TSHA 2.1M
- Earning Date
- HOND 01-01-0001
- TSHA 02-26-2025
- Dividend Yield
- HOND N/A
- TSHA N/A
- EPS Growth
- HOND N/A
- TSHA N/A
- EPS
- HOND N/A
- TSHA N/A
- Revenue
- HOND N/A
- TSHA $9,915,000.00
- Revenue This Year
- HOND N/A
- TSHA N/A
- Revenue Next Year
- HOND N/A
- TSHA N/A
- P/E Ratio
- HOND N/A
- TSHA N/A
- Revenue Growth
- HOND N/A
- TSHA N/A
- 52 Week Low
- HOND $9.97
- TSHA $1.19
- 52 Week High
- HOND $11.57
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- HOND N/A
- TSHA 46.14
- Support Level
- HOND N/A
- TSHA $1.46
- Resistance Level
- HOND N/A
- TSHA $1.76
- Average True Range (ATR)
- HOND 0.00
- TSHA 0.15
- MACD
- HOND 0.00
- TSHA 0.01
- Stochastic Oscillator
- HOND 0.00
- TSHA 39.33
About HOND HCM II ACQUISITION CORP
HCM II Acquisition Corp is a blank check company.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.